Liquidia Co. (NASDAQ:LQDA) CFO Sells $45,722.88 in Stock

Liquidia Co. (NASDAQ:LQDA) CFO Michael Kaseta sold 3,136 shares of the firm’s stock in a transaction on Friday, April 12th. The stock was sold at an average price of $14.58, for a total value of $45,722.88. Following the completion of the sale, the chief financial officer now directly owns 315,045 shares of the company’s stock, valued at approximately $4,593,356.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Michael Kaseta also recently made the following trade(s):

• On Monday, March 18th, Michael Kaseta sold 12,166 shares of Liquidia stock. The stock was sold at an average price of $15.82, for a total value of $192,466.12.

Liquidia Price Performance

Shares of Liquidia stock opened at $13.29 on Friday. The business has a fifty day simple moving average of $14.74 and a two-hundred day simple moving average of $10.97. Liquidia Co. has a 12 month low of $5.71 and a 12 month high of $16.99.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings data on Wednesday, March 13th. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.19). The firm had revenue of $4.53 million for the quarter, compared to analysts’ expectations of $5.29 million. Liquidia had a negative net margin of 448.89% and a negative return on equity of 132.16%. On average, sell-side analysts anticipate that Liquidia Co. will post -1.01 earnings per share for the current year.

Hedge Funds Weigh In On Liquidia

Several large investors have recently modified their holdings of the stock. BlackRock Inc. raised its position in shares of Liquidia by 1.7% in the 2nd quarter. BlackRock Inc. now owns 3,292,967 shares of the company’s stock worth $25,850,000 after purchasing an additional 54,260 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Liquidia by 2.5% in the 4th quarter. Vanguard Group Inc. now owns 2,843,922 shares of the company’s stock worth $34,212,000 after purchasing an additional 69,524 shares during the last quarter. Kynam Capital Management LP raised its position in shares of Liquidia by 34.9% in the 4th quarter. Kynam Capital Management LP now owns 2,698,324 shares of the company’s stock worth $32,461,000 after purchasing an additional 698,324 shares during the last quarter. State Street Corp raised its position in shares of Liquidia by 2.2% in the 1st quarter. State Street Corp now owns 2,656,906 shares of the company’s stock worth $18,359,000 after purchasing an additional 56,373 shares during the last quarter. Finally, Findell Capital Management LLC purchased a new position in shares of Liquidia in the 4th quarter worth about $25,095,000. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently commented on LQDA. Needham & Company LLC reaffirmed a “buy” rating and issued a $28.00 price target on shares of Liquidia in a research note on Wednesday, April 10th. HC Wainwright raised their price objective on Liquidia from $16.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, March 14th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, Liquidia has an average rating of “Moderate Buy” and an average price target of $21.00.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).